Plutonium ion, Americium ion, Curium ion (Pu (for plutonium), Am (for americium), Cm (for curium))

Plutonium ion (Pu³⁺), americium ion (Am³⁺), and curium ion (Cm³⁺) are radioactive actinide metal ions that do not have endogenous biological targets or normal physiological roles in humans or other organisms[3][6][7]. These ions are intensely radioactive, decaying primarily by alpha emission, and are mainly encountered as contaminants from nuclear fuel cycles, nuclear weapons programs, or rare industrial and medical sources[3][4][6][7]. The +3 oxidation state is the most stable aqueous form for americium and curium; plutonium exhibits a wider range of oxidation states (+3, +4, +5, +6)[4][5][7]. Following accidental incorporation (e.g., by inhalation, ingestion, wounds), these ions deposit especially in bone and liver, where they cause radiotoxic damage due to their alpha particles[3][7]. Their removal from the body is extremely slow; some isotopes remain in tissues for decades[3]. The primary medical intervention is intravenous chelation therapy (e.g., with DTPA) to enhance the elimination of actinides[3]. There are no current pharmaceutical agonists or antagonists, nor are these ions considered receptors, enzymes, or conventional drug targets. Their monitoring is relevant mainly for radiation safety and accident treatment[6][7]. Collectively, these ions are classified as hazardous environmental contaminants and radiological threats in accidental exposure, not as molecular targets for therapeutic pharmacology.

Other names

Plutonium(III) ion, Pu³⁺Americium(III) ion, Am³⁺Curium(III) ion, Cm³⁺Actinide ions (collective group)

Chelation: chelators bind actinide ions to facilitate their excretion from the body